CeriBell First Quarter 2025 Earnings: Beats Expectations

CeriBell (NASDAQ:CBLL) First Quarter 2025 Results

Key Financial Results

• Revenue: US$20.5m (up 38% from 1Q 2024).
• Net loss: US$12.8m (loss widened by 46% from 1Q 2024).
• US$0.36 loss per share.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

CeriBell Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are down 2.1% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for CeriBell (1 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.